Lubeck Deborah P
Department of Medicine, Stanford University, USA.
Pharmacoeconomics. 2004;22(2 Suppl 1):27-38. doi: 10.2165/00019053-200422001-00004.
Patients with rheumatoid arthritis (RA) face considerable physical, social and emotional disabilities. In this chronic disease, for which a cure is not yet available, improving patients' health-related quality of life (HRQoL) is of the utmost concern, particularly as the use of long-term and potentially toxic therapy increases. Early HRQoL outcome measures in RA focused on physical functioning, but the social and emotional aspects of the disease are now increasingly important. Thus, several generic and RA-specific HRQoL instruments have been developed, but no one tool covers all areas of HRQoL that affect the patient with RA. For this reason, a combination of generic and disease-specific tools is currently recommended for RA clinical trials.
类风湿性关节炎(RA)患者面临着相当大的身体、社会和情感方面的残疾。在这种尚无治愈方法的慢性疾病中,改善患者的健康相关生活质量(HRQoL)是最为重要的关注点,尤其是随着长期且可能有毒性的治疗方法的使用增加。RA早期的HRQoL结果测量主要集中在身体功能方面,但该疾病的社会和情感方面如今变得越来越重要。因此,已经开发了几种通用的和针对RA的HRQoL工具,但没有一种工具能涵盖影响RA患者的HRQoL的所有领域。出于这个原因,目前建议在RA临床试验中结合使用通用工具和疾病特异性工具。